Recently, finerenone, a nonsteroidal mineralocorticoid receptor (MR) antagonist, has been shown in clinical trials to slow CKD progression in patients with T2D when combined with RAS inhibitors.2 The gene discussed is NR3C2; the disease is chronic kidney disease.